Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies
The immunomodulatory agent, lenalidomide, is a structural analogue of thalidomide approved by the US Food and Drug Administration for the treatment of myelodysplastic syndrome (MDS) and multiple myeloma (MM). This agent is also currently under active investigation for the treatment of chronic lympho...
| Published in: | Advances in Hematology |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Online Access: | http://dx.doi.org/10.1155/2012/513702 |